spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

TAT 2018 – Targeted Anticancer Therapies

European Society for Medical Oncology (ESMO)

5-7 March 2018
Paris Marriott Rive Gauche Hotel & Conference Centre

The constant evolution of early phase development and translational research drove ESMO to enrich its meeting portfolio by acquiring the TAT Congress and providing a discussion platform focusing on new molecular targets and innovative cancer therapeutics.

A prestigious scientific committee, led jointly by G. Giaccone and J. Tabernero, designed a cutting-edge programme, establishing the TAT 2018 Congress as the premier international anticancer drug development meeting bringing together academia, industry, clinicians, researchers, scientists and regulators.

The goals and the design of phase 1 studies have changed from just safety/toxicity to now include clinical activity/response and biomarker research. This new phase 1 paradigm has already led to rapid, conditional, approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies.

TAT focuses on early-phase development and translational research. The programme will cover targeted agents, immuno-oncology and combinations involving such agents. We hope to see you at TAT 2018!

phone +41 (0)91 973 15 81
email registration@esmo.org
web https://www.esmo.org/Conferences/ESMO-Targeted-Anticancer-Therapies-Congress-2020
 
Print this page
Send to a friend
   
spacer
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>


News and Press Releases

Sense Accelerates Instrument-Free Molecular Diagnostic Test for COVID-19

April 1, 2020 – Sense Biodetection Limited (Sense) has today announced an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement